Screener
ANI Pharmaceuticals ANIP Rare Disease and Brands — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| (in thousands) | Generics and Other | Rare Disease and Brands | Corporate and Unallocated | Total |
|---|---|---|---|---|
| Selling, general, and administrative expense | 1,578 | 60,719 | 29,364 | 91,661 |
| Depreciation and amortization | — | — | 19,640 | 19,640 |
| Contingent consideration fair value adjustment | — | — | (622) | (622) |
| Operating Income (Loss) | $36,494 | $52,348 | $(48,382) | $40,460 |
| Unrealized gain on investment in equity securities | — | — | $741 | $741 |
| Interest expense, net | — | — | (3,636) | (3,636) |
| Other expense, net | — | — | (468) | (468) |
| Income (Loss) Before Income Tax Expense | $36,494 | $52,348 | $(51,745) | $37,097 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's rare disease and brands — operating income (loss)?
- ANI Pharmaceuticals (ANIP) reported rare disease and brands — operating income (loss) of $52.35M in Q2 2026.
- How has ANI Pharmaceuticals's rare disease and brands — operating income (loss) changed year-over-year?
- ANI Pharmaceuticals's rare disease and brands — operating income (loss) increased by 77.7% year-over-year, from $29.46M to $52.35M.
- What is the long-term trend for ANI Pharmaceuticals's rare disease and brands — operating income (loss)?
- Over 3 years (2022 to 2025), ANI Pharmaceuticals's rare disease and brands — operating income (loss) has grown at a 137.5% compound annual growth rate (CAGR), from $10.54M to $141.24M.
- What does rare disease and brands — operating income (loss) mean?
- Measures the profitability of the Rare Disease and Brands segment by subtracting operating expenses from net revenues. It is a key performance indicator for evaluating the segment's ability to generate sustainable earnings from its core business activities.
Ask your AI about ANI Pharmaceuticals's rare disease and brands — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude